Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Core Viewpoint - Genprex, Inc. has entered into an exclusive license agreement with the University of Michigan for its lead drug candidate, Reqorsa® Gene Therapy, in combination with ALK-inhibitors for the treatment of ALK-positive lung cancer [1][2]. Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its ONCOPREX® Delivery System to administer disease-fighting genes [6]. - The company is currently evaluating Reqorsa® Gene Therapy in two clinical trials for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [6]. Product Details - Reqorsa® Gene Therapy (quaratusugene ozeplasmid) targets cancer cells by delivering the TUSC2 gene using non-viral nanoparticles, aiming to interrupt cancer cell signaling and promote apoptosis [4]. - The therapy has shown positive preclinical data, indicating its potential effectiveness in treating ALK-positive lung cancer, particularly in patients resistant to alectinib [2][3]. Research and Development - Research at the University of Michigan has demonstrated that Reqorsa can decrease cell growth and proliferation in ALK-positive NSCLC cell lines by activating apoptotic pathways [3]. - The company believes that Reqorsa may be an effective treatment for patients progressing on ALK inhibitors, supporting further clinical studies [3]. Intellectual Property Strategy - Genprex is enhancing its intellectual property portfolio for Reqorsa, which may benefit patients with various types of cancers, thereby widening its exclusivity for drug combinations [2].